A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Clinical trial NCT06785636 · RECRUITING

Trial details

NCT number: NCT06785636
Sponsor: Pathos AI, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

mCRPC (Metastatic Castration-resistant Prostate Cancer)Prostate Cancer

Start date: 2025-02-07
Primary completion: 2028-06-30
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.